Released April 12, 2021 | BEIJING, CHINA
en
Researched by Industrial Info Resources (Sugar Land, Texas)--The COVID-19 pandemic has sparked a sharp rise in China's vaccine production, as the country seeks to protect its citizens and export its vaccines abroad.
So far, the domestic use of China's self-produced COVID-19 vaccine has exceeded 150 million doses, and the export volume has exceeded 100 million doses. The China Vaccine Industry Association revealed that COVID-19 vaccine capacity is expected to reach 5 billion doses next year. The production is strictly controlled by the state.
In addition to vaccine regulation, China has implemented a policy of mass procurement of medicines. The Chinese government's volume purchases are mainly based on generic drugs and basic drugs, which generally lack demand elasticity.
Before the outbreak of COVID-19, Flu and Japanese Encephalitis vaccines were the most used in China.
Industrial Info's Global Market Intelligence (GMI) platform follows 16 operational vaccine plants in China, along with four active projects, worth $617.75 million.
Click here for a list of related plants and here for related projects, and see graph below showing the plant count by operational status.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com.
So far, the domestic use of China's self-produced COVID-19 vaccine has exceeded 150 million doses, and the export volume has exceeded 100 million doses. The China Vaccine Industry Association revealed that COVID-19 vaccine capacity is expected to reach 5 billion doses next year. The production is strictly controlled by the state.
In addition to vaccine regulation, China has implemented a policy of mass procurement of medicines. The Chinese government's volume purchases are mainly based on generic drugs and basic drugs, which generally lack demand elasticity.
Before the outbreak of COVID-19, Flu and Japanese Encephalitis vaccines were the most used in China.
Industrial Info's Global Market Intelligence (GMI) platform follows 16 operational vaccine plants in China, along with four active projects, worth $617.75 million.
Click here for a list of related plants and here for related projects, and see graph below showing the plant count by operational status.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com.
